PDCD1 and non-small cell lung carcinoma: Nivolumab, an anti-PD-1 mAb, is approved for treatment of head and neck squamous cell cancer (HNSCC), Hodgkin lymphoma, advanced melanoma, non-small cell lung cancer (NSCLC), renal cell cancer, and urothelial cancer.